DIAZOXIDE TOPICAL SOLUTION BEING DEVELOPED AS HAIR GROWTH PRODUCT by Lakatos-Topol Research Institute, the company announced in a Feb. 24 press release. Lakatos-Topol said it obtained an exclusive license to the product, except in Japan, from a physician in Detroit who developed a method to put diazoxide in solution. The original mfr. of diazoxide is Schering-Plough, which markets the drug in injectable form for treatment of hypertension under the brandname Hyperstat, and, at one time, marketed an oral formulation, called Proglycem, for management of hypoglycemia. Lakatos-Topol said Medical Market Specialties, Inc., located in Cedar Grove, N.J., currently markets Proglycem. Lakatos-Topol said it believes diazoxide is superior to Upjohn's Regaine (minoxidil) as a hair growth stimulant. The firm's release claims that diazoxide "produces a longer and thicker growth of hair" than the Upjohn product. Upjohn's minoxidil is also marketed as an antihypertensive under the tradename Loniten. Upjohn has an NDA pending for the topical dosage form for treatment of male pattern baldness and alopecia areata. Lakatos-Topol said it has begun testing the hair growth product outside the U.S. and requested FDA permission to conduct tests in the U.S. An IND has not yet been filed. The firm has also applied for a U.S. patent. Based in Houston, Texas, Lakatos-Topol was formed in July 1985 and went public in January. In its initial offering, the firm said it "intends to engage in cancer research and the business of research and development of diagnostic, treatment, and therapeutic products incorporating monoclonal antibodies created by means of hybridoma technology or 'cell fusions.'" Lakatos-Topol said it raised $125,000 from its initial offering and needs to raise an additional $2 mil. to carry out development of three projects. In addition to diazoxide, the company said it acquired an exclusive license, except in Japan, to monoclonal antibodies to malignant melanoma and monoclonal antibodies to squamous cell carcinoma and basal cell carcinoma. Lakatos-Topol also reported that it is developing monoclonal antibodies to LDHK (lactate dehydrogenase K), an enzyme that the firm said is found solely in cancer cells. In its filing, the company said it anticipates contracting for R&D and clinical testing and "subcontracting with and/or licensing established mfrs. for production and marketing of some, or possibly all, of its products."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
